机械通气卒中患者生命支持限制决策的多中心前瞻性研究
这项法国14个ICU的多中心前瞻性观察研究纳入2005至2016年机械通气的373例卒中患者(缺血性167例,出血性206例)和5683例非脑损伤患者,评估生命支持限制(不启动或撤除)决策的频率及相关因素。缺血性卒中41%做出限制决策(与非脑损伤相比,亚分布风险比3.59,95%CI 2.78-4.65),出血性卒中33%(亚分布风险比3.9,95%CI 2.97-5.11)。缺血性卒中从ICU入住到首次限制的时间长于出血性卒中(5[3-9]天 vs 2[1-6]天,P<0.01),限制决策先于ICU死亡的比例分别为70%和45%(P<0.01)。缺血性卒中椎基底动脉部位和卒中前改良Rankin评分大于2增加限制风险,出血性卒中年龄大于70岁和格拉斯哥昏迷评分小于8增加风险,而非神经系统入ICU序贯器官衰竭评估评分较高与风险降低相关。
要点
- 机械通气卒中患者生命支持限制决策常见:缺血性卒中41%,出血性卒中33%,均显著高于非脑损伤患者的3倍以上。
- 缺血性卒中限制决策时间较出血性卒中晚(5[3-9]天 vs 2[1-6]天,P<0.01),且更常先于ICU死亡(70% vs 45%,P<0.01)。
- 缺血性卒中椎基底动脉部位(亚分布风险比1.61,95%CI 1.01-2.59)和卒中前改良Rankin评分大于2(2.38,95%CI 1.27-4.55)与限制风险增加相关。
- 出血性卒中年龄大于70岁(亚分布风险比2.29,95%CI 1.43-3.69)和格拉斯哥昏迷评分小于8(2.15,95%CI 1.08-4.3)与限制风险增加相关。
- 出血性卒中非神经系统入ICU序贯器官衰竭评估评分每增加1分与限制风险降低相关(亚分布风险比0.89,95%CI 0.82-0.97)。
适用人群与场景
- 2005至2016年法国14个ICU中,卒中患者和非脑损伤患者,均在入ICU 24小时内需要侵入性机械通气。
- 卒中患者包括缺血性卒中167例(45%)和出血性卒中206例(55%)。
研究设计与关键结果
- 多中心前瞻性法国观察性研究,纳入14个ICU,373例卒中患者(缺血性167例,出血性206例)和5683例非脑损伤患者。
- 生命支持限制决策:缺血性卒中41%(与非脑损伤相比,亚分布风险比3.59,95%CI 2.78-4.65),出血性卒中33%(亚分布风险比3.9,95%CI 2.97-5.11)。
- 从ICU入住到首次限制的时间:缺血性卒中5[3-9]天 vs 出血性卒中2[1-6]天,P<0.01。
- 限制决策先于ICU死亡:缺血性卒中70% vs 出血性卒中45%,P<0.01。
- 缺血性卒中限制风险增加因素:椎基底动脉部位(与前一循环相比,亚分布风险比1.61,95%CI 1.01-2.59),卒中前改良Rankin评分大于2(2.38,95%CI 1.27-4.55)。
- 出血性卒中限制风险增加因素:年龄大于70岁(亚分布风险比2.29,95%CI 1.43-3.69),格拉斯哥昏迷评分小于8(2.15,95%CI 1.08-4.3);非神经系统入ICU序贯器官衰竭评估评分每增加1分与风险降低相关(0.89,95%CI 0.82-0.97)。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在机械通气卒中患者中,生命支持限制决策在缺血性和出血性卒中均常见,且频率高于非脑损伤患者,临床中应意识到这一差异。
- 缺血性卒中限制决策时间较出血性卒中晚,且更常先于ICU死亡,床旁决策时需考虑卒中类型对限制时机的影响。
- 缺血性卒中患者若为椎基底动脉部位或卒中前改良Rankin评分大于2,限制决策风险更高;出血性卒中患者若年龄大于70岁或格拉斯哥昏迷评分小于8,限制决策风险更高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The determinants of decisions to limit life support (withholding or withdrawal) in ventilated stroke patients have been evaluated mainly for patients with intracranial hemorrhages. We aimed to evaluate the frequency of life support limitations in ventilated ischemic and hemorrhagic stroke patients compared with a nonbrain-injured population and to determine factors associated with such decisions.
DESIGN: Multicenter prospective French observational study.
SETTING: Fourteen ICUs of the French OutcomeRea network.
PATIENTS: From 2005 to 2016, we included stroke patients and nonbrain-injured patients requiring invasive ventilation within 24 hours of ICU admission.
MEASUREMENTS AND MAIN RESULTS: We identified 373 stroke patients (ischemic, n = 167 [45%]; hemorrhagic, n = 206 [55%]) and 5,683 nonbrain-injured patients. Decisions to limit life support were taken in 41% of ischemic stroke cases (vs nonbrain-injured patients, subdistribution hazard ratio, 3.59 [95% CI, 2.78-4.65]) and in 33% of hemorrhagic stroke cases (vs nonbrain-injured patients, subdistribution hazard ratio, 3.9 [95% CI, 2.97-5.11]). Time from ICU admission to the first limitation was longer in ischemic than in hemorrhagic stroke (5 [3-9] vs 2 d [1-6] d; p < 0.01). Limitation of life support preceded ICU death in 70% of ischemic strokes and 45% of hemorrhagic strokes (p < 0.01). Life support limitations in ischemic stroke were increased by a vertebrobasilar location (vs anterior circulation, subdistribution hazard ratio, 1.61 [95% CI, 1.01-2.59]) and a prestroke modified Rankin score greater than 2 (2.38 [1.27-4.55]). In hemorrhagic stroke, an age greater than 70 years (2.29 [1.43-3.69]) and a Glasgow Coma Scale score less than 8 (2.15 [1.08-4.3]) were associated with an increased risk of limitation, whereas a higher nonneurologic admission Sequential Organ Failure Assessment score was associated with a reduced risk (per point, 0.89 [0.82-0.97]).
CONCLUSIONS: In ventilated stroke patients, decisions to limit life support are more than three times more frequent than in nonbrain-injured patients, with different timing and associated risk factors between ischemic and hemorrhagic strokes.
参考来源
- de Montmollin E, Schwebel C, Dupuis C, et al. Life Support Limitations in Mechanically Ventilated Stroke Patients. Crit Care Explor. 2021. PMID: 33634264. doi:10.1097/CCE.0000000000000341
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。